Azitra (NYSEAMERICAN:AZTR – Get Free Report) released its earnings results on Wednesday. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.39, FiscalAI reports.
Azitra Trading Down 11.4%
Shares of AZTR stock traded down $0.05 during mid-day trading on Thursday, reaching $0.36. 623,013 shares of the company’s stock traded hands, compared to its average volume of 1,884,517. Azitra has a 12 month low of $0.35 and a 12 month high of $4.33. The firm has a 50 day moving average price of $0.66 and a two-hundred day moving average price of $1.25.
Wall Street Analyst Weigh In
Separately, Maxim Group dropped their price target on shares of Azitra from $13.32 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, September 24th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $4.00.
Azitra Company Profile
Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.
Further Reading
- Five stocks we like better than Azitra
- What is Put Option Volume?
- AMD to $300 Looks Easy—Here’s Why $500 Could Be Next
- P/E Ratio Calculation: How to Assess Stocks
- $5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You
- Why Are These Companies Considered Blue Chips?
- 4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
